4 Can these agents that increase the levels of GLP-1 alter the course of type 2 diabetes in humans
Figure 1 Data extraction The first authors name, year and country of publication, age of the participants, females%, study type, number of participants, the study duration, duration of diabetes, body mass index, type of GLP-1 agonist, total side effects, number of hyper and hypoglycemia, time spent in hypoglycemia, time spent in hyperglycemia, and C-peptibe level we recorded in excel sheet
It arises from the C-cells
Lab work: Your provider may require baseline lab work (blood glucose, lipid panel, metabolic panel) and periodic monitoring labs
It reduces the production of reactive oxygen species (ROS) and decreases the expression of NADPH oxidase 2 (NOX2), NOX4, and ICAM-1 in human umbilical vein endothelial cells (HUVECs)
10.1097/FJC.0000000000000258 99